Avidity Biosciences, Inc. (RNA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | 3,847 | 1,573 | 2,336 | 2,045 |
| Research and development | 138,125 | 99,490 | 77,197 | 63,940 |
| General and administrative | 36,864 | 33,600 | 23,273 | 20,731 |
| Total operating expenses | 174,989 | 133,090 | 100,470 | 84,671 |
| Loss from operations | -171,142 | -131,517 | -98,134 | -82,626 |
| Other expense | -651 | -435 | -232 | -116 |
| Interest income | 14,478 | 16,179 | 17,968 | 11,949 |
| Total other income | 13,827 | 15,744 | 17,736 | 11,833 |
| Net loss | -157,315 | -115,773 | -80,398 | -70,793 |
| Net unrealized (losses) gains on marketable securities | -1,084 | -170 | 7,555 | 11 |
| Foreign currency translation adjustment | 96 | 34 | - | - |
| Comprehensive loss | -158,303 | -115,909 | -72,843 | -70,782 |
| Net loss per share, basic (in dollars per share) | -1.21 | -0.9 | -0.65 | -0.65 |
| Net loss per share, diluted (in dollars per share) | -1.21 | -0.9 | -0.65 | -0.65 |
| Weighted-average shares outstanding, basic (in shares) | 129,622,000 | 129,232,000 | 123,375,000 | 106,928,000 |
| Weighted-average shares outstanding, diluted (in shares) | 129,622,000 | 129,232,000 | 123,375,000 | 106,928,000 |